NIMH Chemical Synthesis & Drug Supply Program (CDSP)

NIMH化学合成和药物供应计划的目的是合成、纯化和提供无法从商业来源获得的基本化合物（例如，库存已耗尽且不会补充，正在进行临床试验时无法获得的专利化合物等），以刺激与精神健康相关的基础和临床研究，如分子药理学和中枢神经系统受体信号传导。评估精神活性化合物的分子、生化和行为作用的纵向研究，以及灵长类动物和人类的功能性脑成像。目前的计划重点是合成用于基础和临床研究的现行GMP（良好生产规范）和非GMP化合物，如新型中枢神经系统受体亚型选择性激动剂和拮抗剂，放射性标记化合物，以及用于功能性脑成像的新型PET， SPECT和fMRI配体。

The purpose of the NIMH Chemical Synthesis and Drug Supply Program is to synthesize, purify, and provide essential compounds that are unavailable from commercial sources (e.g., the stock has been depleted and it will not be replenished, patented compounds that are unavailable while undergoing clinical trials, etc.) to stimulate basic and clinical research relevant to mental health in areas such as the molecular pharmacology and signaling of CNS receptors, longitudinal studies to evaluate the molecular, biochemical, and behavioral actions of psychoactive compounds, and functional brain imaging in primates and humans. The present initiative focuses on the synthesis of current GMP (Good Manufacturing Practices) and non-GMP compounds for basic and clinical research such as novel central nervous system receptor subtype-selective agonists and antagonists, radiolabeled compounds, and novel PET, SPECT, and fMRI ligands for functional brain imaging.